CytoNiche Biotech

CytoNiche Biotech Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from CytoNiche Biotech, Biotechnology company, 1 FUSIONOPOLIS LINK #06-06, NEXUS@ONE-NORTH, Singapore.

CytoNiche™ revolutionizes CGT manufacturing with 3D FloTrix™ technology, offering GMP-grade dissolvable microcarriers, serum-free media for MSCs, and GMP-compliant equipment to support expansion, harvesting, processing, and filling.

11/09/2026

What separates a promising exosome therapy from a manufacturable one?

As exosome programmes move towards clinical translation, therapeutic potential is only part of the equation. Consistent, reproducible manufacturing is becoming equally important.

In our latest episode, we explore three key considerations:

🔹 Producer cell health throughout the process
🔹 Consistency across successive harvests
🔹 Functional consistency of the resulting EVs

The industry is shifting from experience-driven development to data-driven manufacturing, with greater emphasis on process understanding, standardisation, and reproducibility.

🎥 Watch the full episode to explore what this shift means for the future of exosome manufacturing.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/27.html

07/09/2026

Can EV production be made more efficient without simply adding more culture vessels?

In our latest Cell Architects episode, we share results from a 16-day high-density MSC perfusion culture using chemically defined, animal component-free medium and 3D recombinant collagen microcarriers.

Compared with conventional 2D culture, the process achieved approximately 3× higher EV particle production per volume of medium, with consistently high cell viability and maintained MSC phenotype.

Using a compact 5 L bioreactor, the process has the potential to produce 10¹⁴–10¹⁵ EV particles per batch, while offering greater scalability, process control, and sampling flexibility.

🎥 Watch the full episode to explore the data behind scalable EV manufacturing.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/27.html

We came to ISCT Asia to talk about scaling cells.But scaling advanced therapies is about much more than increasing cell ...
04/09/2026

We came to ISCT Asia to talk about scaling cells.

But scaling advanced therapies is about much more than increasing cell numbers.

It is about building a manufacturing process that can deliver consistent quality, reproducible performance, and regulatory compliance—at scale.

Over the past three days at Booth 14, CytoNiche engaged with researchers, clinicians, manufacturers, and industry leaders on the challenges of moving cell therapies from promising science towards clinical and commercial reality.

One message came through clearly: as the industry advances, manufacturing and regulatory requirements must advance with it.

From process development and closed-system workflows to scalable production and GMP-aligned manufacturing, the path to commercialisation requires technologies designed with both process performance and regulatory expectations in mind.

We thank everyone who visited Booth 14 and shared their perspectives with us.

The future of advanced therapies will not be defined by scale alone, but by the ability to scale with quality, consistency, and compliance.

We’re here in Singapore!Today marks the first day of ISCT Asia Regional Meeting 2026, and we’re excited to connect with ...
02/09/2026

We’re here in Singapore!

Today marks the first day of ISCT Asia Regional Meeting 2026, and we’re excited to connect with the global cell therapy community at Booth 14.

From cell expansion to downstream processing and final fill, CytoNiche is bringing our integrated manufacturing technologies to Singapore to showcase how we can support the journey from process development to clinical and commercial manufacturing.

Whether you’re looking to optimise your current process, scale up production, or explore new possibilities for your cell therapy workflow, we’d love to meet you and exchange ideas.

📅 2–4 September 2026
📍 Booth 14 | Suntec Singapore Convention & Exhibition Centre

Come by Booth 14 — let’s turn conversations into collaborations and ideas into breakthroughs.

See you there!

31/08/2026

Why does scaling exosome production remain such a challenge?

As exosome-based therapies progress towards clinical translation, the focus is shifting from proof-of-concept research to scalable, reproducible, and controllable manufacturing.

Traditional 2D culture, hollow fibre systems, and fixed-bed bioreactors each offer advantages, but also present limitations when it comes to scalability, process visibility, and culture uniformity.

In this episode, we take a closer look at these upstream manufacturing approaches and explore how microcarrier-based suspension culture can provide a scalable platform for MSC expansion in stirred-tank bioreactors.

From real-time process monitoring to controlled culture conditions, the manufacturing strategy chosen upstream can have a significant impact on downstream consistency and ultimately, clinical translation.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/27.html

The booth closes in Jakarta, but the culture continues. Next stop, Singapore!Three days at ACTO 2026 come to a close. It...
28/08/2026

The booth closes in Jakarta, but the culture continues. Next stop, Singapore!

Three days at ACTO 2026 come to a close. It has been a valuable opportunity for our team to meet experts from across the cell therapy community, exchange perspectives, while gaining valuable insights into the evolving needs of cell and gene therapy manufacturing.

What stood out at ACTO 2026 was not just the breadth of the discussions, but how closely they reflected the realities of moving cell therapy from development towards more scalable manufacturing. From upstream expansion and cell processing to automation and process integration, the conversations centred on a common question: how do we make cell manufacturing more scalable without adding unnecessary complexity?

Thank you to everyone who stopped by Booth 4, shared your experiences and took a closer look at what we are building at CytoNiche. Every conversation gave us a clearer view of where the industry is heading — and where manufacturing needs to evolve next.

We would like to express our sincere appreciation to the ACTO 2026 organising team for putting together such a successful event and creating a valuable platform for learning, discussion, and collaboration.

Missed us on the exhibition floor or didn’t get a chance to connect? No worries — we’re still here to help scale past your challenges. Feel free to reach out to our team or join us at ISCT Asia in Singapore, and let’s find work through them together.

The only thing we'll be expanding next week isn't just cells—it's new collaborations.In less than one week, CytoNiche wi...
27/08/2026

The only thing we'll be expanding next week isn't just cells—it's new collaborations.

In less than one week, CytoNiche will be at ISCT Asia Regional Meeting 2026, where the global cell therapy community comes together to exchange ideas, share the latest advancements, and explore what's next for the industry.

Stop by Booth 14 to see our technologies in action and discover how our integrated manufacturing solutions can help accelerate your journey from process development to clinical and commercial manufacturing.

📅 2–4 September 2026
📍 Booth 14 | Suntec Singapore Convention & Exhibition Centre, Singapore

Let's start a conversation that could lead to your next breakthrough.

See you in Singapore!

Day 1 at ACTO 2026! A strong start to three days in Jakarta💪Our team has had the opportunity to meet researchers, clinic...
26/08/2026

Day 1 at ACTO 2026! A strong start to three days in Jakarta💪

Our team has had the opportunity to meet researchers, clinicians, manufacturers, and industry professionals from across the cell therapy community, with many engaging conversations on the challenges and opportunities in cell and gene therapy manufacturing.

From cell expansion and processing to scale-up and manufacturing, it has been valuable to hear different perspectives and learn more about the work happening across the industry.

Thank you to everyone who visited Booth 4 today. We look forward to continuing the conversations and meeting more of you over the next two days.

📍 Booth 4 | Hotel Borobudur, Jakarta
📅 26–28 August 2026

If you’re at ACTO 2026, we’d be happy to connect.

What does it take to manufacture millions of therapeutic doses of extracellular vesicles (EVs)—without compromising qual...
24/08/2026

What does it take to manufacture millions of therapeutic doses of extracellular vesicles (EVs)—without compromising quality or consistency?

As MSC-derived EVs move towards commercialisation, manufacturing is becoming the key differentiator. In our latest article, we explore how integrated, GMP-oriented manufacturing strategies can improve scalability, process consistency, and product quality—from upstream cell expansion to downstream purification and final fill-finish.

Discover why manufacturing excellence will be just as important as biological efficacy in the next generation of EV therapeutics.

📄 Read the full article here: https://en.cytoniche.com/notes_detail/27.html

What does it really take to turn an advanced therapy into a reliable, scalable treatment?It starts with more than scient...
23/08/2026

What does it really take to turn an advanced therapy into a reliable, scalable treatment?

It starts with more than scientific innovation. It starts with GMP.

We’re pleased to share that CytoNiche Biotech will be participating as a speaker at CITCI 2026 in Guadalajara, Mexico, where we’ll explore:

🔬 Why Do Advanced Therapies Require True GMP?

As cell and gene therapies move from research towards clinical and commercial applications, manufacturing must evolve alongside the science. Consistency, process control, scalability, and quality are becoming essential to turning promising therapies into reproducible products.

At CITCI 2026, we look forward to discussing the role of true GMP in advanced therapy manufacturing and the manufacturing strategies needed to support the next generation of cell-based therapies.

📍 Guadalajara, Mexico
📅 September 8, 2026

We look forward to connecting with researchers, developers, and industry leaders shaping the future of advanced therapies.

See you at CITCI 2026!

Address

1 FUSIONOPOLIS LINK #06-06, NEXUS@ONE-NORTH
Singapore
138542

Opening Hours

Monday 09:00 - 18:00
Tuesday 09:00 - 18:00
Wednesday 09:00 - 18:00
Thursday 09:00 - 18:00
Friday 09:00 - 18:00

Website

Alerts

Be the first to know and let us send you an email when CytoNiche Biotech posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to CytoNiche Biotech:

Shortcuts

Share

Category